Selective FTO Inhibitor Compounds With Reduced COMT Interference

Solution Overview

Problem

Existing FTO inhibitors, such as entacapone, exhibit non-selective inhibition of COMT, leading to potential side effects and adverse drug-drug interactions, necessitating the development of novel FTO inhibitors with improved selectivity over COMT inhibition.

Innovation Solution

Development of compounds with specific structural modifications to enhance FTO inhibition while minimizing COMT inhibition, including variations in L1, L2, L3, R1, R2, R3, R4, and R5 groups, forming a compound of Formula (I) or its pharmaceutically acceptable salts, stereoisomers, or deuterated analogs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If entacapone is used as an FTO inhibitor, then FTO inhibition is achieved, but COMT inhibition occurs leading to side effects and drug interactions

Engineering Contradiction:

ImproveFTO inhibition efficacyVSAvoidCOMT inhibition side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by introducing specific substituent groups (R1-R5) at different positions of the entacapone molecular structure. These localized modifications at specific sites (ortho, meta, para positions) selectively enhance FTO inhibition while reducing COMT inhibition, allowing different parts of the molecule to have differentiated functions for target selectivity

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying substituent types (halogen, alkyl, alkoxy, nitro, cyano groups) and their positions on the molecular structure. These chemical parameter modifications alter the molecule's binding affinity and selectivity, transforming entacapone from a non-selective inhibitor to a selective FTO inhibitor with improved safety profile

Inventive Principle:

Principle #35Parameter changes

2Reliability

If entacapone is used as an FTO inhibitor, then FTO inhibition is achieved, but adverse drug-drug interactions occur due to COMT inhibition

Engineering Contradiction:

ImproveFTO inhibition efficacyVSAvoidadverse drug interactions

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by introducing specific substituent groups (R1-R5) at different positions of the entacapone molecular structure. These localized modifications at specific sites (ortho, meta, para positions) selectively enhance FTO inhibition while reducing COMT inhibition, allowing different parts of the molecule to have differentiated functions for target selectivity

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying substituent types (halogen, alkyl, alkoxy, nitro, cyano groups) and their positions on the molecular structure. These chemical parameter modifications alter the molecule's binding affinity and selectivity, transforming entacapone from a non-selective inhibitor to a selective FTO inhibitor with improved safety profile

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260035341A1FTO inhibitors

Publication Date: 2026.02.05 RPXDS CO LTD

AI summary

Provided are a compound of Formula (I) as an FTO inhibitor with improved and selective FTO inhibition, a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.